PL3953357T3 - Pochodne pirolotriazyny do leczenia chorób mediowanych przez KIT i PDGFRA - Google Patents

Pochodne pirolotriazyny do leczenia chorób mediowanych przez KIT i PDGFRA

Info

Publication number
PL3953357T3
PL3953357T3 PL20721083.2T PL20721083T PL3953357T3 PL 3953357 T3 PL3953357 T3 PL 3953357T3 PL 20721083 T PL20721083 T PL 20721083T PL 3953357 T3 PL3953357 T3 PL 3953357T3
Authority
PL
Poland
Prior art keywords
pdgfra
mediated diseases
pyrrolotriazine derivatives
treating kit
kit
Prior art date
Application number
PL20721083.2T
Other languages
English (en)
Inventor
Joseph L. Kim
Thomas A. Dineen
Timothy Guzi
Original Assignee
Blueprint Medicines Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70416596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3953357(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Blueprint Medicines Corporation filed Critical Blueprint Medicines Corporation
Publication of PL3953357T3 publication Critical patent/PL3953357T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL20721083.2T 2019-04-12 2020-04-08 Pochodne pirolotriazyny do leczenia chorób mediowanych przez KIT i PDGFRA PL3953357T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962833529P 2019-04-12 2019-04-12
US201962911016P 2019-10-04 2019-10-04
US201962930240P 2019-11-04 2019-11-04
PCT/US2020/027177 WO2020210293A1 (en) 2019-04-12 2020-04-08 Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases

Publications (1)

Publication Number Publication Date
PL3953357T3 true PL3953357T3 (pl) 2024-09-02

Family

ID=70416596

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20721083.2T PL3953357T3 (pl) 2019-04-12 2020-04-08 Pochodne pirolotriazyny do leczenia chorób mediowanych przez KIT i PDGFRA

Country Status (33)

Country Link
US (2) US10829493B2 (pl)
EP (2) EP4424312A3 (pl)
JP (2) JP7600140B2 (pl)
KR (1) KR102875260B1 (pl)
CN (1) CN113939515B (pl)
AU (1) AU2020272743B2 (pl)
BR (1) BR112021020441A2 (pl)
CA (1) CA3136802A1 (pl)
CL (1) CL2021002656A1 (pl)
CO (1) CO2021015113A2 (pl)
DK (1) DK3953357T3 (pl)
EC (1) ECSP21080096A (pl)
ES (1) ES2980811T3 (pl)
FI (1) FI3953357T3 (pl)
HR (1) HRP20240702T1 (pl)
HU (1) HUE067299T2 (pl)
IL (1) IL287168B2 (pl)
LT (1) LT3953357T (pl)
MA (1) MA55604B1 (pl)
MD (1) MD3953357T2 (pl)
MX (1) MX2021012469A (pl)
MY (1) MY209048A (pl)
PE (1) PE20212331A1 (pl)
PH (1) PH12021552568A1 (pl)
PL (1) PL3953357T3 (pl)
PT (1) PT3953357T (pl)
RS (1) RS65644B1 (pl)
SG (1) SG11202111244XA (pl)
SI (1) SI3953357T1 (pl)
SM (1) SMT202400229T1 (pl)
TW (1) TWI857043B (pl)
WO (1) WO2020210293A1 (pl)
ZA (1) ZA202108104B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3782998B1 (en) * 2018-04-16 2023-05-10 Shenzhen TargetRx, Inc. Substituted pyrrolotriazine compound, pharmaceutical composition thereof and use thereof
US10829493B2 (en) * 2019-04-12 2020-11-10 Blueprint Medicines Corporation Compositions and methods for treating KIT- and PDGFRA-mediated diseases
US20230391780A1 (en) * 2020-10-14 2023-12-07 Blueprint Medicines Corporation Compositions and methods for treating kit- and pdgfra-mediated diseases
CN117098760B (zh) * 2020-10-14 2026-04-14 缆图药品公司 用于治疗kit和pdgfra介导的疾病的组合物和方法
HU231413B1 (hu) 2021-02-26 2023-08-28 Egis Gyógyszergyár Zrt. Eljárás avapritinib és intermedierek előállítására
IL305611A (en) 2021-03-03 2023-11-01 Blueprint Medicines Corp Synthetic methods and intermediates for the production of compounds for the treatment of PDGFRA-mediated diseases and kits
CN117794935A (zh) * 2021-03-10 2024-03-29 缆图药品公司 激酶抑制剂的盐和固体形式
KR20240013720A (ko) * 2021-03-10 2024-01-30 블루프린트 메디신즈 코포레이션 키나아제 저해제의 염 및 고체 형태
CN113278023B (zh) * 2021-07-22 2021-10-15 上海睿跃生物科技有限公司 含氮杂环化合物及其制备方法和应用
CA3237696A1 (en) * 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2024171143A1 (en) * 2023-02-17 2024-08-22 Assia Chemical Industries Ltd. Salts and solid forms of elenestinib

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61238784A (ja) 1985-04-17 1986-10-24 Sumitomo Seiyaku Kk コハク酸イミド誘導体及びその酸付加塩
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
DE60026297T2 (de) 1999-05-21 2006-11-02 Bristol-Myers Squibb Co. Pyrrolotriazin kinasehemmer
WO2001025220A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
KR101025675B1 (ko) 2002-04-23 2011-03-30 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 피롤로-트리아진 아닐린 화합물
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
KR101312736B1 (ko) 2003-02-27 2013-09-27 팔라우 파르마 에스에이 피라졸로피리딘 유도체
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
WO2006028524A2 (en) 2004-04-29 2006-03-16 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CA2627839C (en) 2005-11-02 2014-08-19 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
MX2008009557A (es) 2006-01-27 2009-01-07 Shanghai Hengrui Pharm Co Ltd Inhibidores de la cinasa de proteina de la pirrolo [3,2-c] piridin-4-ona-2-indolinona.
HRP20140688T1 (hr) 2006-07-07 2014-10-24 Bristol-Myers Squibb Company Inhibitori piroltriazin kinaze
KR20100038108A (ko) 2007-07-25 2010-04-12 브리스톨-마이어스 스큅 컴퍼니 트리아진 키나제 억제제
ES2413806T3 (es) 2008-03-20 2013-07-17 Amgen Inc. Moduladores de la aurora cinasa y método de uso
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
AU2010259009A1 (en) 2009-06-08 2012-01-12 Nantbioscience, Inc. Triazine derivatives and their therapeutical applications
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
MX2012009561A (es) 2010-02-17 2012-11-23 Amgen Inc Carboxamidas como inhibidores de canales de sodio dependientes del voltaje.
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CN102040494A (zh) 2010-11-12 2011-05-04 西北师范大学 对氟苯甲醛的制备方法
PE20140570A1 (es) 2011-07-01 2014-04-28 Bayer Ip Gmbh Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
MX2015002887A (es) 2012-09-06 2015-07-06 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
EP2935248B1 (en) 2012-12-21 2018-02-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
WO2017019442A1 (en) 2015-07-24 2017-02-02 Blueprint Medicines Corporation Compounds useful for treating disorders related to kit and pdgfr
PL3371171T3 (pl) 2015-11-02 2024-03-25 Blueprint Medicines Corporation Inhibitory RET
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
KR102398659B1 (ko) 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
US11040979B2 (en) * 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
CN109400610A (zh) 2017-08-18 2019-03-01 浙江海正药业股份有限公司 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途
CN108191874B (zh) 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
EP3782998B1 (en) 2018-04-16 2023-05-10 Shenzhen TargetRx, Inc. Substituted pyrrolotriazine compound, pharmaceutical composition thereof and use thereof
MX2020011501A (es) 2018-05-04 2020-12-07 Inflazome Ltd Compuestos novedosos.
US20220010382A1 (en) 2018-11-12 2022-01-13 Blueprint Medicines Corporation Avapritinib resistance of kit mutants
MA54526A (fr) 2018-12-20 2022-03-30 Pfizer NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta
US10829493B2 (en) 2019-04-12 2020-11-10 Blueprint Medicines Corporation Compositions and methods for treating KIT- and PDGFRA-mediated diseases
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
CN110950872A (zh) 2019-12-25 2020-04-03 武汉九州钰民医药科技有限公司 制备靶向抗癌药avapritinib的方法
CN110938077B (zh) 2019-12-25 2021-04-27 武汉九州钰民医药科技有限公司 合成Avapritinib的方法
US20230391780A1 (en) 2020-10-14 2023-12-07 Blueprint Medicines Corporation Compositions and methods for treating kit- and pdgfra-mediated diseases

Also Published As

Publication number Publication date
CN113939515B (zh) 2024-06-18
CA3136802A1 (en) 2020-10-15
EP4424312A2 (en) 2024-09-04
PH12021552568A1 (en) 2022-07-04
MY209048A (en) 2025-06-18
MD3953357T2 (ro) 2024-09-30
LT3953357T (lt) 2024-07-25
CO2021015113A2 (es) 2022-02-28
ECSP21080096A (es) 2022-02-25
EP4424312A3 (en) 2025-01-08
HUE067299T2 (hu) 2024-10-28
CN113939515A (zh) 2022-01-14
BR112021020441A2 (pt) 2021-12-14
KR20220025704A (ko) 2022-03-03
MA55604A (fr) 2022-02-16
AU2020272743A1 (en) 2021-11-11
SMT202400229T1 (it) 2024-07-09
PT3953357T (pt) 2024-07-24
MA55604B1 (fr) 2024-08-30
SI3953357T1 (sl) 2024-08-30
CL2021002656A1 (es) 2022-08-26
IL287168B1 (en) 2025-06-01
ES2980811T3 (es) 2024-10-03
IL287168B2 (en) 2025-10-01
WO2020210293A1 (en) 2020-10-15
EP3953357A1 (en) 2022-02-16
PE20212331A1 (es) 2021-12-14
FI3953357T3 (fi) 2024-07-15
HRP20240702T1 (hr) 2024-08-16
JP2022526850A (ja) 2022-05-26
AU2020272743B2 (en) 2025-10-16
JP7600140B2 (ja) 2024-12-16
US12552795B2 (en) 2026-02-17
MX2021012469A (es) 2022-01-18
DK3953357T3 (en) 2024-06-10
RS65644B1 (sr) 2024-07-31
SG11202111244XA (en) 2021-11-29
JP2025029094A (ja) 2025-03-05
TW202104231A (zh) 2021-02-01
ZA202108104B (en) 2024-02-28
KR102875260B1 (ko) 2025-10-23
IL287168A (en) 2021-12-01
US20200325141A1 (en) 2020-10-15
US20220153748A1 (en) 2022-05-19
US10829493B2 (en) 2020-11-10
TWI857043B (zh) 2024-10-01
EP3953357B1 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
IL287168A (en) Kit of pyrrolotriazine derivatives for the treatment of diseases mediated by pdgfra
IL277333A (en) Methods for treating eye diseases
IL277190A (en) Methods of treating HPV-related diseases
IL287907A (en) Cancer treatment methods
CA3280142A1 (en) Compounds for treating alpha-1 antitrypsin-mediated diseases
LT3728271T (lt) Makrocikliniai junginiai, skirti ligų gydymui
IL291735A (en) Heteroarylbiphenylamines for the treatment of pd-l1 diseases
SMT202500493T1 (it) Metodi per il trattamento dell'iperfenilalaninemia
SG11202108636SA (en) Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
GB201909468D0 (en) Compounds for treating cancer
IL276639A (en) Materials and methods for the treatment of dysproliferative diseases
IL290770A (en) Compounds and methods for treating oxalate-related diseases
GB201908885D0 (en) Therapeutic compounds
GB201909466D0 (en) Compounds for treating cancer
HK40076432A (en) Compounds and methods for treating oxalate-related diseases
HK40072711A (en) Dosing regimens for treating or preventing c5-associated diseases
HK40078516A (zh) 诱导肿瘤消退的方法
HK40067840A (en) Methods for treating ocular diseases
HK40058903A (en) Therapeutic methods for treating hepatitis b
GB201911574D0 (en) Therapeutic compounds
GB201911580D0 (en) Therapeutic compounds
GB201907813D0 (en) Therapeutic compounds
HK40036198A (en) Methods for treating ocular diseases
GB201903599D0 (en) Therapeutic compounds
GB201903597D0 (en) Therapeutic compounds